Equity Profile
Pre-Earnings Brief
Kiniksa Pharmaceuticals (KNSA) is a biotechnology company focused on developing treatments for autoimmune and inflammatory diseases. With a market cap of $3 billion, it plays a significant role in the health care sector, addressing unmet medical needs through innovative therapies.
EPS
Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.
Revenue
Revenue figures provide insight into the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
38%
Avg EPS Surprise
-127.87%
Avg Stock Reaction
+4.11%
In the last quarter, Kiniksa reported an EPS of $0.17, which was below analysts' expectations of $0.29, leading to a stock decline of 8.21% the following day. The company did not provide revenue figures, which adds uncertainty to its performance evaluation.
Management Promises & Guidance
Analysts expect Kiniksa to report an EPS of $0.16 and revenue of $206 million for Q1-2026. There is cautious optimism given the company's recent history of earnings surprises, but concerns linger due to past misses.
Bull Case
If Kiniksa meets or exceeds the EPS and revenue expectations, it could signal strong demand for its products and effective cost management, potentially leading to a positive stock reaction.
Bear Case
Conversely, if the company misses its targets again, it may raise concerns about its growth trajectory and market competitiveness, potentially resulting in a further decline in stock price.
EPS
$0.16Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.
Revenue
$206MRevenue figures provide insight into the company's sales performance and market demand for its products.
Expectations
The print will turn on these two things.
Q1
Will Kiniksa's EPS meet or exceed the consensus estimate of $0.16?
This figure is crucial as it will indicate the company's profitability and could significantly impact investor sentiment.
Q2
What revenue figure will Kiniksa report, and how does it compare to the consensus of $206 million?
Revenue performance will provide insight into market demand for Kiniksa's products and overall business health.
Edge
Why consensus could be wrong
The Street may be underestimating Kiniksa's ability to rebound from past earnings misses, as recent product developments could drive stronger-than-expected demand.
Supporting Evidence
Kiniksa has a history of surprising the market positively, as seen in Q2-2025 where it beat expectations significantly.
The company's focus on innovative treatments may lead to increased sales that are not fully reflected in current estimates.
Key Risk
If Kiniksa's revenue exceeds $210 million, it could challenge the current bearish sentiment.
Edge
Pre-commit to what would confirm each case.
This quarter's performance is pivotal as Kiniksa seeks to recover from recent earnings misses and demonstrate sustainable growth.
Bull Confirmed If
An EPS of $0.16 or higher, coupled with revenue exceeding $206 million, would confirm a strong operational performance.
Bear Confirmed If
An EPS below $0.13 or revenue below $201 million would suggest ongoing challenges in meeting market expectations.
Pre-Earnings Positioning
Implied Move
±4.2%
Historical Avg
±10.8%
The options market is pricing in a modest move for Kiniksa's stock around the earnings announcement, reflecting uncertainty about the results.
Options are pricing ±3.7% while KNSA has averaged ±10.8% over the last 8 prints — setup is pricing cheap.
30d HV
33.7%
Edge
Cross-company pattern from 30 similar setups.
Prior-quarter miss setup in Health Care
n=30Fade rate: 10 of 27 (37%)
This setup has occurred 30 times across Health Care in the last 2 years. 17 of 27 (63%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 6.7%, with a raw directional average of +3.7% (modestly positive historical bias).
Edge
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$388,834.32
8,328 sh
2 insiders
Net
$388,834.32
Net selling
Most Active Insiders· 2 open-market trades
$309,321.25
Net selling
$79,513.07
Net selling
Recent Transactions
Apr 9, 2026 · @ $46.69
6,625 sh
$309,321.25
Apr 9, 2026 · @ $46.69
1,703 sh
$79,513.07
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Preparation
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Kiniksa beats expectations, history suggests a positive stock reaction averaging around +18.59%, confirming a recovery in investor confidence.
In-Line / Cautious
If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance from management.
Miss
Should Kiniksa miss its targets, the stock could drop by an average of -4.58%, reflecting ongoing concerns about its growth prospects.
Preparation
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
DOMINOS PIZZA INC